Vertex Pharmaceuticals Gross Profit

As of the most recent data (June 2026), VRTX shows a gross profit of $11B. That compares with $9.8B in the prior-year period — up 10.1% year over year. That is below the Healthcare sector average of $65B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, VRTX's gross profit is now $11B (was $9.8B) — a 10.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Vertex Pharmaceuticals is outperforming or lagging.

The Healthcare sector average gross profit is about $65B. Vertex Pharmaceuticals is at $11B, which is lower that average. That is roughly 83.3% below the sector mean. Use the comparison chart on this page to see how VRTX stacks up against individual peers as well.

Tracking VRTX's gross profit over time shows whether Vertex Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $11B That compares with $9.8B in the prior-year period — up 10.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this gross profit page, Stockcircle has Vertex Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect gross profit (currently $11B) with ownership activity and broader fundamentals.